Scholarlink

<p>The human microbiome is a complex ecosystem that produces a diverse repertoire of bioactive molecules essential for maintaining physiological homeostasis. Growing evidence indicates that microbiome-derived metabolites, including secondary bile acids, short-chain fatty acids (SCFAs), polyamines, vitamins, tryptophan-derived metabolites and microbial bioactive compounds, play vital roles not only in modulating immune responses and metabolic pathways but also in maintaining epithelial integrity and regulating systemic inflammation. Through their effects on host signaling pathways, these molecules act as key mediators in the development and progression of metabolic diseases and cancer. This review discusses how such molecules influence the tumor microenvironment, regulate epigenetic processes, such as histone deacetylase inhibition, and modulate metabolic pathways, including lipid homeostasis, adipogenesis, and insulin sensitivity. Emerging therapeutic approaches, including probiotics, postbiotics, and fecal microbiota transplantation, highlight the translational potential of microbiome-targeted interventions. Postbiotics comprise preparations of inanimate microorganisms and/or their components that confer health benefits and should be distinguished from purified microbial metabolites. Despite advancements in this field, challenges remain, including the standardization of metabolites and inter-individual variability in the microbiome, which can hinder widespread application. Future perspectives emphasize not only multi-omics technology but also the significant impact of personalized microbiome medicine, bioprospecting for novel metabolites, and computational modeling. Collectively, these findings highlight the therapeutic landscape of microbiome-derived molecules and their potential to transform interventional strategies for metabolic diseases and even cancer. This review synthesizes current knowledge on major classes of microbiome-derived metabolites, emphasizing their origins, mechanisms of action, and roles in disease modulation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Microbiome-derived bioactive molecules regulate host signaling and therapeutic responses in cancer and metabolic diseases

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月25日

查看全文
  • Tuayyeb Hussain Nadeem Hussain,
  • Tuahir Hassan Nadeem Hussain,
  • Jyoti Bhagat,
  • Asiya Nazir

摘要

The human microbiome is a complex ecosystem that produces a diverse repertoire of bioactive molecules essential for maintaining physiological homeostasis. Growing evidence indicates that microbiome-derived metabolites, including secondary bile acids, short-chain fatty acids (SCFAs), polyamines, vitamins, tryptophan-derived metabolites and microbial bioactive compounds, play vital roles not only in modulating immune responses and metabolic pathways but also in maintaining epithelial integrity and regulating systemic inflammation. Through their effects on host signaling pathways, these molecules act as key mediators in the development and progression of metabolic diseases and cancer. This review discusses how such molecules influence the tumor microenvironment, regulate epigenetic processes, such as histone deacetylase inhibition, and modulate metabolic pathways, including lipid homeostasis, adipogenesis, and insulin sensitivity. Emerging therapeutic approaches, including probiotics, postbiotics, and fecal microbiota transplantation, highlight the translational potential of microbiome-targeted interventions. Postbiotics comprise preparations of inanimate microorganisms and/or their components that confer health benefits and should be distinguished from purified microbial metabolites. Despite advancements in this field, challenges remain, including the standardization of metabolites and inter-individual variability in the microbiome, which can hinder widespread application. Future perspectives emphasize not only multi-omics technology but also the significant impact of personalized microbiome medicine, bioprospecting for novel metabolites, and computational modeling. Collectively, these findings highlight the therapeutic landscape of microbiome-derived molecules and their potential to transform interventional strategies for metabolic diseases and even cancer. This review synthesizes current knowledge on major classes of microbiome-derived metabolites, emphasizing their origins, mechanisms of action, and roles in disease modulation.